Viral hepatitis B and C in children

Journal of the Royal Society of Medicine

Volumn 99, Issue 7, 2006, Pages 353-357

  Kelly, Deirdre ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTISENSE OLIGODEOXYNUCLEOTIDE; CYTOKINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; PEGINTERFERON; PREDNISOLONE; RIBAVIRIN;

ANTIBODY TITER; ANTIGEN DETECTION; CHILD; CLINICAL TRIAL; DISEASE COURSE; DRUG INHIBITION; HEPATITIS B; HEPATITIS C; HISTORY; HUMAN; LIVER BIOPSY; LIVER TRANSPLANTATION; REVIEW; SEROCONVERSION; VIRUS TRANSMISSION;

EID: 33746487353     PISSN: 01410768     EISSN: None     Source Type: Journal    
DOI: 10.1258/jrsm.99.7.353     Document Type: Review

References (37)

1. Bellentani S, Pozzato G, Saccoccio G. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999;44:874-80
2. Chu CM. Natural history of chronic hepatitis B virus infection in adults: emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatotol 2000;15(suppl):E25-30
3. Lee WS, McKiernan P, Kelly DA. Etiology, outcome and prognostic indicators of childhood fulminant hepatic failure in the United Kingdom. J Paediat Gastroenterol Nutr 2005;40:575-81
4. Chang MH. Viral mutants and fulminant hepatitis. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. J Pediat Gastroenterol Nutr 2002;34:426
5. Bramley JC, Wallace LA, Ahmed S, et al. Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study. Commun Dis Publ Health 2002;5:318-20
6. Boxall EH, Sira J, El-Shukri N, Kelly DA. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Inject Dis 2004;190:1264-9
7. Petersen KM, Bulkow LR, McMahon MD, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Inject Dis J 2004;23:650-5
8. Chang MH, Chen CJ, Lai MS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-5
9. Boxall EH, Sira J, Standish RA, et al. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed 2004; 89:456-60
10. Bortolotti F, Jara P, Crivello C, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998;29:184-90
11. Moore SW, Millar AJ, Hadley GP, et al. Hepatocellular carcinoma and liver tumors in South African children: a case for increased prevalence. Cancer 2004;101:642-9
12. Jara P, Bortolotti F. Interferon-α treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediat Gastroenterol Nutr 1999;29:163-70
13. Bortolotti F, Jara P, Barbera C, et al. Long term affect of alpha interferon in children with chronic hepatitis B. Gut 2000;46:715-18
14. Krogsgaard K, Marcellin P, Trepo C. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group. J Hepatol 1996;25:803-13
15. Jonas M, Kelly D, Mizerski J. Clinical trial of Lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13
16. Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr Drugs 2002;4:361-9
17. Marcellin P, Chang TT, Lim SG, et al. Adefovir Dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16
18. Hadziyannis S, Tassopoulos NC, Heathcote EJ, et al. for the Adefovir Dipivoxil 438 Study Group. Long-term therapy with Adefovir Dipivoxil 438 Study Group. N Engl J Med 2005;352:2673-81
19. Terrault NA. Treatment of recurrent hepatitis B infection in liver transplant recipients. Liver Transpl 2002;8(suppl 1):S74-81
20. Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004;78:955-63
21. Lau GKK, Piratvisuth T, Luo KX, et al. for the Peginterferon Alfa-2A HBeAG-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95
22. Choo QL, Kuo G, Weiner AJ Overby, LR Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A non-B viral hepatitis genome. Science 1989;224:359-62
23. Honda M, Kaneko S, Sakai A. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 1994;20: 1141-51
24. Bunn SK, Sire J, Brown R, Kelly DA. Hepatitis C: a single UK centre experience. Arch Dis Childh 2006;91(Suppl):A16
25. Gibb DM, Neave P, Tookey PA, et al. Active surveillance of hepatitis C infection in the UK and Ireland. Arch Dis Childh 2000;82:286-92
26. Thomas SL, Newell ML, Peckham CS, Ades AF, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemol 1998;27:108-17
27. Resti M, Azzari C, Mannelli F, Tuscany Study Group on hepatitis C infection in children. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. BMJ 1998;317:437-41
28. Resti M, Bortolotti F, Vajro P, Maggiore G, Committee of Hepatology of the Italian Society of Pediatric Gastroenterology and Hepatology. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig Liver Dis 2003;35:453-7
29. Ruiz-Extremera A, Salmeron J, Torres C. Follow-up of transmission of hepatitis C to babies of human immunodeficiency virus-negative women: the role of breast-feeding in transmission. Pediat Infect Dis J 2000;19:511-16
30. European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. Br J Obstet Gjnaecol 2001;108:371-7
31. Roberts EA, King SM, Fearon M, McGee N. Hepatitis C in children after transfusion: assessment by look-back studies. Acta Gastroenterol Belg 1998;61:195-7
32. Vogt M, Lang T, Frosner G. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood donor screening. N Engl J Med 1999;341:866-70
33. Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European paediatric hepatitis C virus infection. J Infect Dis 2000;181:419-24
34. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology 2001; 33:321-7
35. Badizadegan K, Jonas M, Ott MJ. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998;28:1416-23
36. Gonzalez-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b ribavirin for children with chronic hepatitis C: efficacy, safety and pharmacokinetics. Hepatology 2005;42:1010-18
37. Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis B. Hepatology 2005;41:1013-18